4
MARKET OVERVIEW
Maps the market evolution with focus on trend catalysts, risk factors, and growth opportunities across segments.
4.3
UNMET NEEDS & WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Covers the key developments, trend analysis, and actionable insights to support strategic planning and positioning.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN EUROPE PHARMACEUTICAL FILTRATION MARKET
5.5.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT (2022–2025)
5.5.2
AVERAGE SELLING PRICE TREND, BY COUNTRY (2022–2025)
5.6.1
IMPORT SCENARIO (HS CODE 8421)
5.6.2
EXPORT SCENARIO (HS CODE 8421)
5.7
KEY CONFERENCES & EVENTS, 2025–2026
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9
INVESTMENT & FUNDING SCENARIO
5.9.1
VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
5.10
IMPACT OF 2025 US TARIFFS ON EUROPE PHARMACEUTICAL FILTRATION MARKET
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON COUNTRIES
5.10.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
ELECTROSPUN MICROFIBERS
6.2.2
PHOTOCATALYTIC FILTRATION
6.3
ADJACENT TECHNOLOGIES
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.7
IMPACT OF AI/GEN AI ON EUROPE PHARMACEUTICAL FILTRATION MARKET
6.7.1
TOP USE CASES & MARKET POTENTIAL
6.7.2
CASE STUDIES OF AI IMPLEMENTATION IN EUROPE PHARMACEUTICAL FILTRATION MARKET
6.7.3
INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.7.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN EUROPE PHARMACEUTICAL FILTRATION MARKET
7
SUSTAINABILITY & REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS & COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.3
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
EUROPE PHARMACEUTICAL FILTRATION MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
9.2.1.1
MEMBRANE FILTERS, BY TYPE OF MATERIAL
9.2.1.1.1
PES (POLYETHERSULFONE)
9.2.1.1.2
PVDF (POLYVINYLIDENE DIFLUORIDE)
9.2.1.1.4
PTFE (POLYTETRAFLUOROETHYLENE)
9.2.1.1.5
MCE & CA (MIXED CELLULOSE ESTER & CELLULOSE ACETATE)
9.2.1.1.6
PCTE (POLYCARBONATE TRACK-ETCHED)
9.2.1.1.7
OTHER MATERIALS
9.2.1.2
DEPTH FILTERS, BY MEDIA
9.2.2.1
DIATOMACEOUS EARTH
9.2.2.5
OTHER DEPTH FILTER MEDIA
9.3.1
FILTRATION ASSEMBLIES
9.3.1.1
MICROFILTRATION ASSEMBLIES
9.3.1.2
ULTRAFILTRATION ASSEMBLIES
9.3.1.3
NANOFILTRATION ASSEMBLIES
9.3.1.4
OTHER FILTRATION ASSEMBLIES
9.3.3
FILTRATION ACCESSORIES
10
EUROPE PHARMACEUTICAL FILTRATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION)
NOTE 6: OTHER TECHNIQUES INCLUDE REVERSE OSMOSIS, ION EXCHANGE, AND PRE-FILTRATION (COARSE FILTRATION)
11
EUROPE PHARMACEUTICAL FILTRATION MARKET, BY TYPE, 2023–2030 (USD MILLION)
11.3
NON-STERILE FILTRATION
12
EUROPE PHARMACEUTICAL FILTRATION MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
12.2
FINAL PRODUCT PROCESSING
12.2.1
ACTIVE PHARMACEUTICAL INGREDIENT FILTRATION
12.2.2
PROTEIN PURIFICATION
12.2.3
VACCINES & ANTIBODY PROCESSING
12.2.4
FORMULATION & FILLING SOLUTIONS
12.3
RAW MATERIAL FILTRATION
12.3.1
MEDIA BUFFER FILTRATION
13
EUROPE PHARMACEUTICAL FILTRATION MARKET, BY SCALE OF OPERATION, 2023–2030 (USD MILLION)
14
EUROPE PHARMACEUTICAL FILTRATION MARKET, BY END USER, 2023–2030 (USD MILLION)
14.2
PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
14.4
CROS AND ACADEMIC & RESEARCH INSTITUTES
15
EUROPE PHARMACEUTICAL FILTRATION MARKET, BY REGION, 2023–2030 (USD MILLION)
15.2.8
MACROECONOMIC OUTLOOK OF EUROPE
16.2
KEY PLAYER STRATEGY/ RIGHT TO WIN
16.3
REVENUE ANALYSIS, 2022–2024
16.4
MARKET SHARE ANALYSIS,
16.5
COMPANY EVALUATION MATRIX: KEY PLAYERS
16.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
16.5.5.1
COMPANY FOOTPRINT
16.5.5.2
COUNTRY FOOTPRINT
16.5.5.3
PRODUCT FOOTPRINT
16.5.5.4
TECHNIQUE FOOTPRINT
16.5.5.5
APPLICATION FOOTPRINT
16.6
COMPANY EVALUATION MATRIX: START-UPS/SMES,
16.6.1
PROGRESSIVE COMPANIES
16.6.2
RESPONSIVE COMPANIES
16.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
16.6.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
16.6.5.2
COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
16.7
COMPETITIVE SCENARIO
16.7.3
OTHER DEVELOPMENTS
16.8
BRAND/ PRODUCT COMPARISON
16.9
COMPANY VALUATION & FINANCIAL METRICS
17.1.3
EATON CORPORATION PLC
17.1.5
DONALDSON COMPANY, INC
17.1.6
ALFA LAVAL CORPORATE AB
17.1.8
MANN+HUMMEL INTERNATIONAL GMBH & CO. KG.
18.1.1.1
KEY SOURCES OF SECONDARY DATA
18.1.1.2
KEY OBJECTIVES OF SECONDARY DATA
18.1.2.1
BREAKDOWN OF PRIMARY INTERVIEWS
18.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
18.2
MARKET SIZE ESTIMATION
18.2.1
EUROPE PHARMACEUTICAL FILTRATION MARKET SIZE ESTIMATION
18.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
18.2.1.2
MNM REPOSITORY ANALYSIS
18.2.1.3
SECONDARY ANALYSIS
18.2.1.4
PRIMARY RESEARCH
18.2.1.4.1
INSIGHTS FROM PRIMARY EXPERTS
18.3
MARKET GROWTH RATE PROJECTIONS
18.5
RESEARCH ASSUMPTIONS
18.6
RESEARCH LIMITATIONS & RISK ASSESSMENT
19.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in Europe Pharmaceutical Filtration Market